Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All molnupiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir

Liu et al., Infectious Diseases and Therapy, doi:10.1007/s40121-022-00716-7
Oct 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
ICU admission -162% Improvement Relative Risk Progression 8% Hospitalization time 18% Time to viral- 21% Viral clearance, day 21 -23% Viral clearance, day 14 28% Viral clearance, day 10 38% Viral clearance, day 7 18% Viral clearance, day 5 12% Molnupiravir for COVID-19  Liu et al.  EARLY TREATMENT Is early treatment with molnupiravir beneficial for COVID-19? Retrospective 42 patients in China (March - May 2022) Shorter hospitalization (p=0.14) and faster viral clearance (p=0.1), not sig. c19early.org Liu et al., Infectious Diseases and Th.., Oct 2022 Favorsmolnupiravir Favorscontrol 0 0.5 1 1.5 2+
Retrospective 42 elderly patients in China showing faster viral clearance with molnupiravir.
Potential risks include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-10. Multiple analyses have identified variants potentially created by molnupiravir11-14.
risk of ICU admission, 161.5% higher, RR 2.62, p = 1.00, treatment 1 of 26 (3.8%), control 0 of 16 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of progression, 7.7% lower, RR 0.92, p = 1.00, treatment 3 of 26 (11.5%), control 2 of 16 (12.5%), NNT 104, dyspnea or ICU.
hospitalization time, 17.9% lower, relative time 0.82, p = 0.14, treatment 26, control 16.
time to viral-, 21.4% lower, relative time 0.79, p = 0.10, treatment 26, control 16.
risk of no viral clearance, 23.1% higher, RR 1.23, p = 1.00, treatment 2 of 26 (7.7%), control 1 of 16 (6.2%), day 21.
risk of no viral clearance, 28.2% lower, RR 0.72, p = 0.51, treatment 7 of 26 (26.9%), control 6 of 16 (37.5%), NNT 9.5, day 14.
risk of no viral clearance, 38.5% lower, RR 0.62, p = 0.04, treatment 14 of 26 (53.8%), control 14 of 16 (87.5%), NNT 3.0, day 10.
risk of no viral clearance, 17.9% lower, RR 0.82, p = 0.22, treatment 20 of 26 (76.9%), control 15 of 16 (93.8%), NNT 5.9, day 7.
risk of no viral clearance, 11.5% lower, RR 0.88, p = 0.28, treatment 23 of 26 (88.5%), control 16 of 16 (100.0%), NNT 8.7, day 5.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Liu et al., 30 Oct 2022, retrospective, China, peer-reviewed, median age 84.0, 10 authors, study period 26 March, 2022 - 31 May, 2022. Contact: liangxuesong2000@163.com, 452055289@qq.com, redmaples2005@163.com, 18351977696@163.com, zhongwu@bmi.ac.cn, xuaijing86@163.com, fansy@bmi.ac.cn, 1042956281@qq.com, 617943178@qq.com, yxdongxu@126.com.
This PaperMolnupiravirAll
Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir
Yayun Liu, Lingling Ge, Shiyong Fan, Aijing Xu, Xinyu Wang, Xu Dong, Mingxiao Xu, Wenhan Fan, Wu Zhong, Xuesong Liang
Infectious Diseases and Therapy, doi:10.1007/s40121-022-00716-7
Introduction: The efficacy of molnupiravir (MLN) on Omicron sublineages is limited. We investigated the effectiveness of MLN in older adults diagnosed with Omicron BA.2. Methods: Data of elderly COVID-19 patients (over 60 years) admitted to Chinghai Hospital (Shanghai, China) from 26 March to 31 May 2022 were reviewed. Study outcomes were a composite of undetectable viral load (VL) and disease progression [all-cause mortality, initiation of oxygen supply through high-flow device or invasive mechanical ventilation (IMV), or intensive care unit (ICU) admission] and their individual outcomes. Results: A total of 42 elderly patients were enrolled: 26 of them received MLN, 17 (40.5%) were males, the median age was 84 years, and 12 were fully vaccinated (31.0%). Among these elderly COVID-19 patients, five (11.90%) experienced obvious dyspnea or were transferred to ICU [three MLN users (11.5%) versus two non-MLN users (12.5%)]. Compared with no MLN use, MLN use was associated with rapid undetectable VL. At day 10, MLN users achieved Yayun Liu, Lingling Ge, and Shiyong Fan are co-first authors.
Author Contributions. Yayun Liu recruited the patients and collected specimens, edited the clinical data and performed the data analysis; Lingling Ge edited the clinical data of enrolled patients; Shiyong Fan drafted the manuscript; Aijing Xu recruited the patients and treated the patients; Wang, Xu Dong, Mingxiao Xu and Wenhan Fan treated the patients; Wu Zhong conceived and designed the study; Xuesong Liang conceived and designed the study; checked the data analysis and drafted the manuscript; All authors have read and approved the final manuscript. Disclosures. Yayun Liu, Lingling Ge, Shiyong Fan, Aijing Xu, Xinyu Wang, XuDong, Mingxiao Xu, Wenhan Fan, Wu Zhong and Xuesong Liang declare that they have no competing interests. Compliance with Ethics Guidelines. This study was approved by the Ethics Committee of Changhai Hospital. (CHEC2022-111).Written informed consent was exempted from all the study participants. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Data Availability. All data and analysis results are included in this article. The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. All authors have read and approved the final manuscript. Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction..
References
Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N Engl J Med, doi:10.1056/NEJMoa2116044
Cao, Li, Yang, The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants, Sci Transl Med, doi:10.1126/scitranslmed.abm7621
Dejnirattisai, Huo, Zhou, SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses, Cell, doi:10.1016/j.cell.2021.12.046
Guo, Han, Zhang, SARS-CoV-2 omicron variant: epidemiological features, biological characteristics, and clinical significance, Front Immunol, doi:10.3389/fimmu.2022.877101
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2118542
Islam, Dhawan, Nafady, Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: mutational impacts, concerns, and the possible solutions, Ann Med Surg (Lond), doi:10.1016/j.amsu.2022.103737
Mohsin, Omicron SARS-CoV-2 variant of concern: a review on its transmissibility, immune evasion, reinfection, and severity, Medicine, doi:10.1097/MD.0000000000029165
Smith, Hakim, Leung, COVID-19 mortality and vaccine coverage-Hong Kong Special Administrative Region China, MMWR Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm7115e1
Takashita, Kinoshita, Yamayoshi, Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant, N Engl J Med
Vangeel, Chiu, Jonghe, Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern, Antiviral Res, doi:10.1016/j.antiviral.2022.105252
Wong, Au, Lau, Lau, Cowling et al., Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study, doi:10.1101/2022.05.26.22275631
Wong, Au, Lau, Lau, Cowling et al., nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong's Omicron BA.2 wave: an observational study, doi:10.1101/2022.05.19.22275291
{ 'indexed': { 'date-parts': [[2022, 10, 31]], 'date-time': '2022-10-31T04:44:37Z', 'timestamp': 1667191477310}, 'reference-count': 12, 'publisher': 'Springer Science and Business Media LLC', 'license': [ { 'start': { 'date-parts': [[2022, 10, 30]], 'date-time': '2022-10-30T00:00:00Z', 'timestamp': 1667088000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}, { 'start': { 'date-parts': [[2022, 10, 30]], 'date-time': '2022-10-30T00:00:00Z', 'timestamp': 1667088000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}], 'funder': [ { 'name': 'Key research project of COVID-19 by Changhai hospital of Naval Medical University', 'award': ['COVID-ZD-006', 'COVID-ZD-011']}, {'name': 'the National Key Research and Development Project', 'award': ['2021YFC2300704']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'DOI': '10.1007/s40121-022-00716-7', 'type': 'journal-article', 'created': { 'date-parts': [[2022, 10, 30]], 'date-time': '2022-10-30T17:02:36Z', 'timestamp': 1667149356000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir', 'prefix': '10.1007', 'author': [ {'given': 'Yayun', 'family': 'Liu', 'sequence': 'first', 'affiliation': []}, {'given': 'Lingling', 'family': 'Ge', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shiyong', 'family': 'Fan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Aijing', 'family': 'Xu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xinyu', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xu', 'family': 'Dong', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mingxiao', 'family': 'Xu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Wenhan', 'family': 'Fan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Wu', 'family': 'Zhong', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xuesong', 'family': 'Liang', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 10, 30]]}, 'reference': [ { 'key': '716_CR1', 'doi-asserted-by': 'publisher', 'first-page': '103737', 'DOI': '10.1016/j.amsu.2022.103737', 'volume': '78', 'author': 'F Islam', 'year': '2022', 'unstructured': 'Islam F, Dhawan M, Nafady MH, et\xa0al. Understanding the omicron ' 'variant (B.1.1.529) of SARS-CoV-2: mutational impacts, concerns, and the ' 'possible solutions. Ann Med Surg (Lond). 2022;78:103737. ' 'https://doi.org/10.1016/j.amsu.2022.103737.', 'journal-title': 'Ann Med Surg (Lond).'}, { 'issue': '15', 'key': '716_CR2', 'doi-asserted-by': 'publisher', 'first-page': '545', 'DOI': '10.15585/mmwr.mm7115e1', 'volume': '71', 'author': 'DJ Smith', 'year': '2022', 'unstructured': 'Smith DJ, Hakim AJ, Leung GM, et\xa0al. COVID-19 mortality and vaccine ' 'coverage—Hong Kong Special Administrative Region China, January 6, ' '2022–March 21, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(15):545–8. ' 'https://doi.org/10.15585/mmwr.mm7115e1.', 'journal-title': 'MMWR Morb Mortal Wkly Rep'}, { 'issue': '6', 'key': '716_CR3', 'doi-asserted-by': 'publisher', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'volume': '386', 'author': 'A Jayk Bernal', 'year': '2022', 'unstructured': 'Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et\xa0al. Molnupiravir ' 'for oral treatment of Covid-19 in nonhospitalized patients. N Engl J ' 'Med. 2022;386(6):509–20. https://doi.org/10.1056/NEJMoa2116044.', 'journal-title': 'N Engl J Med'}, { 'issue': '3', 'key': '716_CR4', 'doi-asserted-by': 'publisher', 'first-page': '467', 'DOI': '10.1016/j.cell.2021.12.046', 'volume': '185', 'author': 'W Dejnirattisai', 'year': '2022', 'unstructured': 'Dejnirattisai W, Huo J, Zhou D, et\xa0al. SARS-CoV-2 Omicron-B.1.1.529 ' 'leads to widespread escape from neutralizing antibody responses. Cell. ' '2022;185(3):467-84e15. https://doi.org/10.1016/j.cell.2021.12.046.', 'journal-title': 'Cell'}, { 'key': '716_CR5', 'doi-asserted-by': 'publisher', 'first-page': '877101', 'DOI': '10.3389/fimmu.2022.877101', 'volume': '13', 'author': 'Y Guo', 'year': '2022', 'unstructured': 'Guo Y, Han J, Zhang Y, et\xa0al. SARS-CoV-2 omicron variant: ' 'epidemiological features, biological characteristics, and clinical ' 'significance. Front Immunol. 2022;13:877101. ' 'https://doi.org/10.3389/fimmu.2022.877101.', 'journal-title': 'Front Immunol'}, { 'issue': '19', 'key': '716_CR6', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/MD.0000000000029165', 'volume': '101', 'author': 'M Mohsin', 'year': '2022', 'unstructured': 'Mohsin M, Mahmud S. Omicron SARS-CoV-2 variant of concern: a review on ' 'its transmissibility, immune evasion, reinfection, and severity. ' 'Medicine (Baltimore). 2022;101(19): e29165. ' 'https://doi.org/10.1097/MD.0000000000029165.', 'journal-title': 'Medicine (Baltimore)'}, { 'key': '716_CR7', 'doi-asserted-by': 'publisher', 'author': 'L Cao', 'year': '2022', 'unstructured': 'Cao L, Li Y, Yang S, et\xa0al. The adenosine analog prodrug ATV006 is ' 'orally bioavailable and has preclinical efficacy against parental ' 'SARS-CoV-2 and variants. Sci Transl Med. 2022. ' 'https://doi.org/10.1126/scitranslmed.abm7621.', 'journal-title': 'Sci Transl Med.', 'DOI': '10.1126/scitranslmed.abm7621'}, { 'key': '716_CR8', 'doi-asserted-by': 'publisher', 'author': 'CKH Wong', 'year': '2022', 'unstructured': 'Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world ' 'effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 ' 'inpatients during Hong Kong’s Omicron BA.2 wave: an observational study. ' 'medRxiv. 2022. https://doi.org/10.1101/2022.05.19.22275291.', 'journal-title': 'medRxiv.', 'DOI': '10.1101/2022.05.19.22275291'}, { 'key': '716_CR9', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2022.105252', 'volume': '198', 'author': 'L Vangeel', 'year': '2022', 'unstructured': 'Vangeel L, Chiu W, De Jonghe S, et\xa0al. Remdesivir, molnupiravir and ' 'nirmatrelvir remain active against SARS-CoV-2 omicron and other variants ' 'of concern. Antiviral Res. 2022;198: 105252. ' 'https://doi.org/10.1016/j.antiviral.2022.105252.', 'journal-title': 'Antiviral Res'}, { 'issue': '10', 'key': '716_CR10', 'doi-asserted-by': 'publisher', 'first-page': '995', 'DOI': '10.1056/NEJMc2119407', 'volume': '386', 'author': 'E Takashita', 'year': '2022', 'unstructured': 'Takashita E, Kinoshita N, Yamayoshi S, et\xa0al. Efficacy of antibodies ' 'and antiviral drugs against Covid-19 Omicron variant. N Engl J Med. ' '2022;386(10):995–8.', 'journal-title': 'N Engl J Med'}, { 'key': '716_CR11', 'doi-asserted-by': 'publisher', 'author': 'CKH Wong', 'year': '2022', 'unstructured': 'Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world ' 'effectiveness of molnupiravir and nirmatrelvir/ritonavir against ' 'mortality, hospitalization, and in-hospital outcomes among ' 'community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave ' 'in Hong Kong: an observational study. medRxiv. 2022. ' 'https://doi.org/10.1101/2022.05.26.22275631.', 'journal-title': 'medRxiv', 'DOI': '10.1101/2022.05.26.22275631'}, { 'issue': '15', 'key': '716_CR12', 'doi-asserted-by': 'publisher', 'first-page': '1397', 'DOI': '10.1056/NEJMoa2118542', 'volume': '386', 'author': 'J Hammond', 'year': '2022', 'unstructured': 'Hammond J, Leister-Tebbe H, Gardner A, et\xa0al. Oral nirmatrelvir for ' 'high-risk, nonhospitalized adults with Covid-19. N Engl J Med. ' '2022;386(15):1397–408. https://doi.org/10.1056/NEJMoa2118542.', 'journal-title': 'N Engl J Med'}], 'container-title': 'Infectious Diseases and Therapy', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40121-022-00716-7.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s40121-022-00716-7/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40121-022-00716-7.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 10, 30]], 'date-time': '2022-10-30T17:09:08Z', 'timestamp': 1667149748000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s40121-022-00716-7'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 10, 30]]}, 'references-count': 12, 'alternative-id': ['716'], 'URL': 'http://dx.doi.org/10.1007/s40121-022-00716-7', 'relation': {}, 'ISSN': ['2193-8229', '2193-6382'], 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'container-title-short': 'Infect Dis Ther', 'published': {'date-parts': [[2022, 10, 30]]}, 'assertion': [ { 'value': '8 August 2022', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '12 October 2022', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '30 October 2022', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit